Diego A. Díaz García, Medical Oncologist, CEO and Founder at CánCare – Advanced Specialty in Oncology, shared a post on X:
“TTF-1 negativity in lung adenocarcinoma.
In a multi-cohort analysis (n=3,297), TTF-1 negative LUAD (~15%) showed distinct biology and consistently worse outcomes.
- ICI: ORR 17% vs 28%, mPFS 2.5 vs 4.4 mo, mOS 9.6 vs 20.2 mo
- Chemo-IO: ORR 26% vs 41%, mOS 11.2 vs 23.4 mo
- KRASG12C inhibitors: ORR 13% vs 36%
TTF-1 negativity may identify a high-risk subset with limited benefit from current strategies.”
Title: TTF-1 expression in lung adenocarcinoma: clinicopathologic, genomic, and immunophenotypic correlates and outcomes to immunotherapy-based treatments and KRASG12C inhibitors
Authors: Alessandro Di Federico, Lingzhi Hong, Arielle Elkrief, Rohit Thummalapalli, Alissa J. Cooper, Biagio Ricciuti, Subba Digumarthy, Joao V. Alessi, Pooja Gogia, Grace M. Hambelton, Federica Pecci, Maisam Makarem, Malini M. Gandhi, Edoardo Garbo, Andrea De Giglio, Ambrogio Gagliano, Francesca Sperandi, Francesco Gelsomino, Stefano Scalera, Laura Cipriani, Daniele Marinelli, Giuseppe Lamberti, Narek Shaverdian, Jessica Haradon, Tom Nguyen, Emma Voligny, Marc Ladanyi, Jianjun Zhang, Don L. Gibbons, John V. Heymach, Mizuki Nishino, Scott J. Rodig, Kathleen Pfaff, Xinan Wang, Natasha Rekhtman, Lynette M. Sholl, Jia Luo, Bruce E. Johnson, Pasi A. Janne, Ravi Arvind, Justin F. Gainor, Marcello Maugeri-Saccà, Andrea Ardizzoni, Rebecca S. Heist, Kathryn C. Arbour, Adam J. Schoenfeld, Natalie I. Vokes, Mark M. Awad
Read the full article on Journal of Thoracic Oncology.
Other articles featuring Diego A. Díaz García on OncoDaily.
